Industry Briefs: October 8, 2012 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Industry Briefs: October 8, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.

Company News

Accupac has announced that it is doubling its capacity and expanding its manufacturing capabilities with a 221,000-ft2 addition of its facility in Lakewood, New Jersey. Read More

Almac has expanded its MHRA/FDA-approved, United Kingdom commercial-packaging facility with the acquisition of a Noack N 623 blister-packaging line from Romaco. Read More

In other news, Almac and DSM have signed collaboration agreement in biocatalysis to provide manufacturing services to the pharmaceutical industry. Read More

Bend Research and the Dow Chemical Company have formed an exclusive collaboration to provide science-based, spray-dried dispersion solutions and select enabling new polymers for poorly soluble oral drugs. Read More

Dr. Reddy’s has announced an expansion in the areas of activated mPEG manufacturing and in the development and manufacture of APIs for use in preclinical through to commercial development at its manufacturing facility in Mirfield, United Kingdom. Read More

Encap Drug Delivery and the School of Pharmacy, Queen’s University Belfast have received funding from the Technology Strategy Board and the Scottish Government that will allow both to enter into a collaborative Knowledge Transfer Partnership on hot-melt extrusion. Read More

Mucosis, a Dutch clinical-stage biotechnology company, has signed a research and license option agreement with Crucell Holland, a Dutch developer of vaccines and antibodies. Read More

Oxford PharmaGenesis has opened a new facility in Switzerland. Read More

Penn Pharma underwent a successful FDA inspection at its Tredegar, United Kingdom facility. Read More

Sanofi and Massachusetts General Hospital have launched a collaboration aimed at furthering translational medicine research to develop new treatments for various types of hematological malignancies and solid tumors. Read More

People News

Pharmanet/I3 has appointed Jamil Hantash as director of immunochemistry operations. Read More


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here